Pharma Veterans

More on GLP-1 Medications – Asrar Qureshi’s Blog Post #1138 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1138 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here. Credit: Andres Ayrton Credit: Artem Podrez Preamble I had earlier discussed GLP-1 in my blogpost #1111 of May 26, in relation to the changes in medical aesthetics demand created by these medications. In this blogpost, I talk about these therapies with reference to their economic and public health implications. Some details in this post are taken from Mckinsey article. Link at the end. Beginning in the 2000s, doctors primarily prescribed GLP-1s to help treat type 2 diabetes. But in late 2023, GLP-1s began making headlines for their success in helping people lose weight. Ozempic, Wegovy, and other brands started to become household names and sales rapidly acceler...

GLP-1 Drugs and Medical Aesthetics – The New Dimension – Asrar Qureshi’s Blog Post #1111 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1111 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here. Credit: Andres Ayrton Credit: Dimitriy Ganin Credit: Julia Larson Preamble In recent years, GLP-1 receptor agonist medications such as semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) have revolutionized the world of weight management. Once primarily prescribed to patients with type 2 diabetes, these drugs have rapidly gained popularity for their impressive weight-loss results. But a fascinating ripple effect is now becoming apparent: GLP-1 therapies are not just changing waistlines—they are reshaping the future of the medical aesthetics industry. As more people experience dramatic physical transf...

New Drug Modalities – Asrar Qureshi’s Blog Post 1047 Dear Colleagues! This is Asrar Qureshi’s Blog Post 1047 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com for publishing our contributions here. Credit: Edward Jenner Credit: Ivan Samkov Credit: Jonathan Borba This post is based on Boston Consulting Group article authored by Lu Chen, Brian Bush, Mike Brochu, and Gian King. Link at the end. Preamble The second annual report from BCG reviews the growth of new drug modalities. The report tracks the progress in each of the six categories of novel modalities in terms of number of products and pipeline revenue. It will help to see which modalities are progressing more rapidly and its implication for patients and biopharma companies and investors. For us in Pakistan, most of this may sound completely foreign, but we are already using many of these products. New Modalities L...

The Ozempic® Epidemic – Asrar Qureshi’s Blog Post #868 Dear Colleagues!  This is Asrar Qureshi’s Blog Post #868 for Pharma Veterans. Pharma Veterans aims to share knowledge and wisdom from Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi on  WordPress, the top blog site. Please email to asrar@asrarqureshi.com for publishing your contributions here. Credit: Andes Ayrton Credit: John Diez Credit: nappy The Medicine and the Medical Information Ozempic® is a drug for Type 2 diabetes. It contains active ingredient Semaglutide. It is in the form of injection which should be given once weekly under the skin. Ozempic was approved in December 2017. Semaglutide was developed and marketed by a Danish company, Novo Nordisk. Price for 1mg injection in Pakistan is almost 20,000. Ozempic is available as subcutaneous injection. It belongs to the class of glucagon-like peptide-1 (GLP-1) analog. It is also indicated for reducing the risk of majo...